Elanco (ELAN) Financial Analysis & Valuation | Quarter Chart
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto... more
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $11.25B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Jeffrey N. Simmons |
| IPO Date | 2018-09-20 | CAGR | 4.95% |
| Employees | 9,650 | Website | www.elanco.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ELAN chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $13.81B | P/E | 21.25 | Forward P/E | 21.92 | PEG | 0.4 |
| P/S | 0.02 | P/B | 0.02 | P/CF | 0.03 | P/FCF | 0.03 |
| Sales | $5.02B | Sales 1Y | 11.95% | Sales 3Y | 15.99% | Sales 5Y | 10.32% |
| EPS | $1.06 | EPS 1Y | -146.19% | EPS 3Y | 71.6% | EPS 5Y | -73.51% |
| Sales QoQ | -0.22% | EPS QoQ | — | Sales QoQ Avg | 2.96% | EPS QoQ Avg | 37.6% |
| Gross Margin | 52.59% | Operating Margin | 12.15% | Profit Margin | -3.96% | ROCE | 5.21% |
| ROA | -1% | ROE | -3% | Altman Z Score | 1.34 | Piotroski Score | 5 |
| Current Ratio | 2.05 | Quick Ratio | 1.1 | Cash Ratio | 0.29 | Op. CF Ratio | 0.15 |
| Debt/Equity | 0.59 | Debt/Assets | 0.29 | Lt Debt/Equity | 0.58 | Lt Debt/Cap. | 0.37 |
| Intrst Cov. | 2.36 | Inventory Turnover | 1.35 | Asset Turnover | 0.37 | Receivables Turnover | 4.36 |
| Enterprise Value | $13.81B | P/E Ratio | 21.25 |
| Forward P/E | 21.92 | PEG Ratio | 0.4 |
| P/S Ratio | 0.02 | P/B Ratio | 0.02 |
| P/CF Ratio | 0.03 | P/FCF Ratio | 0.03 |
| EPS | $1.06 | EPS Growth 1Y | -146.19% |
| EPS Growth 3Y | 71.6% | EPS Growth 5Y | -73.51% |
| Revenue Growth 1Y | 11.95% | Gross Margin | 52.59% |
| Operating Margin | 12.15% | Profit Margin | -3.96% |
| ROE | -3% | ROA | -1% |
| ROCE | 5.21% | Current Ratio | 2.05 |
| Quick Ratio | 1.1 | Cash Ratio | 0.29 |
| Debt/Equity | 0.59 | Interest Coverage | 2.36 |
| Altman Z Score | 1.34 | Piotroski Score | 5 |
Elanco (ELAN) valuation & financials
Elanco (ELAN) has a market capitalization of $11.25B and trades at a price-to-earnings ratio of 21.2. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Elanco's revenue grew +12.0% over the last year.
Elanco's next earnings report is scheduled for November 6, 2026 before market open (provider scheduled date); analysts estimate EPS of $0.21. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)